Literature DB >> 27072164

TDO as a therapeutic target in brain diseases.

Cheng-Peng Yu1, Ze-Zheng Pan2, Da-Ya Luo3.   

Abstract

Tryptophan-2, 3-dioxygenase (TDO) is a heme-containing protein catalyzing the first reaction in the kynurenine pathway, which incorporates oxygen into the indole moiety of tryptophan and catalyzes it into kynurenine (KYN). The activation of TDO results in the depletion of tryptophan and the accumulation of kynurenine and its metabolites. These metabolites can affect the function of neurons and inhibit the proliferation of T cells. Increasing evidence demonstrates that TDO is a potential therapeutic target in the treatment of brain diseases as well as in the antitumor and transplant fields. Despite its growing popularity, there are few reviews only focusing on TDO. Hence, we herein review TDO by providing a comprehensive overview of TDO, including its biological functions as well as the evolution, structure and catalytic process of TDO. Additionally, this review will focus on the role of TDO in the pathology of three groups of brain diseases: Schizophrenia, Alzheimer's disease (AD) and Glioma. Finally, we will also provide an opinion regarding the future developmental directions of TDO in brain diseases, especially whether TDO has a potential role in other brain diseases as well as the development and applications of TDO inhibitors as treatments.

Entities:  

Keywords:  Alzheimer’s disease; Glioma; Schizophrenia; TDO; Tryptophan metabolism

Mesh:

Substances:

Year:  2016        PMID: 27072164     DOI: 10.1007/s11011-016-9824-z

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  135 in total

Review 1.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

2.  The adaptive increase of the tryptophan peroxidase-oxidase system of liver.

Authors:  W E KNOX; A H MEHLER
Journal:  Science       Date:  1951-03-02       Impact factor: 47.728

3.  3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims.

Authors:  R Schwarcz; E Okuno; R J White; E D Bird; W O Whetsell
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

Review 4.  Norepinephrine in depressive reactions. A review.

Authors:  W E Bunney; J M Davis
Journal:  Arch Gen Psychiatry       Date:  1965-12

5.  Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum.

Authors:  Arash Rassoulpour; Hui-Qiu Wu; Sergi Ferre; Robert Schwarcz
Journal:  J Neurochem       Date:  2005-05       Impact factor: 5.372

6.  Increased indoleamine 2,3-dioxygenase (IDO) activity in idiopathic generalized epilepsy.

Authors:  Suvi Liimatainen; Kai Lehtimäki; Annika Raitala; Maria Peltola; Simo S Oja; Jukka Peltola; Mikko A Hurme
Journal:  Epilepsy Res       Date:  2011-03-04       Impact factor: 3.045

7.  Inhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by beta-carboline and indole derivatives.

Authors:  N Eguchi; Y Watanabe; K Kawanishi; Y Hashimoto; O Hayaishi
Journal:  Arch Biochem Biophys       Date:  1984-08-01       Impact factor: 4.013

8.  Elevated basal cortisol level predicts lower hippocampal volume and cognitive decline in Alzheimer's disease.

Authors:  Chi-Wei Huang; Chun-Chung Lui; Weng-Neng Chang; Cheng-Hsien Lu; Ya-Ling Wang; Chiung-Chih Chang
Journal:  J Clin Neurosci       Date:  2009-06-30       Impact factor: 1.961

9.  Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases.

Authors:  D Jauch; E M Urbańska; P Guidetti; E D Bird; J P Vonsattel; W O Whetsell; R Schwarcz
Journal:  J Neurol Sci       Date:  1995-05       Impact factor: 3.181

10.  Control of the mRNA for hepatic tryptophan oxygenase during hormonal and substrate induction.

Authors:  G Schutz; L Killewich; G Chen; P Feigelson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-03       Impact factor: 11.205

View more
  15 in total

1.  Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.

Authors:  Shuyu Hao; Guanyou Huang; Jie Feng; Da Li; Ke Wang; Liang Wang; Zhen Wu; Hong Wan; Liwei Zhang; Junting Zhang
Journal:  J Neurooncol       Date:  2019-06-08       Impact factor: 4.130

Review 2.  Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Eric Plitman; Yusuke Iwata; Fernando Caravaggio; Shinichiro Nakajima; Jun Ku Chung; Philip Gerretsen; Julia Kim; Hiroyoshi Takeuchi; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

3.  Targeting the Inhibition of Tryptophan 2,3-Dioxygenase (TDO-2) for Cancer Treatment.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2016-11-22       Impact factor: 4.345

4.  Fluorine-18-Labeled PET Radiotracers for Imaging Tryptophan Uptake and Metabolism: a Systematic Review.

Authors:  Flóra John; Otto Muzik; Sandeep Mittal; Csaba Juhász
Journal:  Mol Imaging Biol       Date:  2020-08       Impact factor: 3.488

Review 5.  Targeting TDO in cancer immunotherapy.

Authors:  Cheng-Peng Yu; Yun-Lei Song; Zheng-Ming Zhu; Bo Huang; Ying-Qun Xiao; Da-Ya Luo
Journal:  Med Oncol       Date:  2017-03-29       Impact factor: 3.064

Review 6.  Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders.

Authors:  Michael Y Bai; David B Lovejoy; Gilles J Guillemin; Rouba Kozak; Trevor W Stone; Maju Mathew Koola
Journal:  Complex Psychiatry       Date:  2021-02-08

7.  Serum kynurenic acid is reduced in affective psychosis.

Authors:  B E Wurfel; W C Drevets; S A Bliss; J R McMillin; H Suzuki; B N Ford; H M Morris; T K Teague; R Dantzer; J B Savitz
Journal:  Transl Psychiatry       Date:  2017-05-02       Impact factor: 6.222

8.  TDO Promotes Hepatocellular Carcinoma Progression.

Authors:  Shanbao Li; Lei Li; Junyi Wu; Fangbin Song; Zhiwei Qin; Lei Hou; Chao Xiao; Junyong Weng; Xuebin Qin; Junming Xu
Journal:  Onco Targets Ther       Date:  2020-06-19       Impact factor: 4.147

9.  TDO2 Promotes the EMT of Hepatocellular Carcinoma Through Kyn-AhR Pathway.

Authors:  Lei Li; Tao Wang; Shanbao Li; Zhengqian Chen; Junyi Wu; Wanyue Cao; Qi Wo; Xuebin Qin; Junming Xu
Journal:  Front Oncol       Date:  2021-01-19       Impact factor: 6.244

10.  Circular RNA circZNF566 promotes hepatocellular carcinoma progression by sponging miR-4738-3p and regulating TDO2 expression.

Authors:  Shanbao Li; Junyong Weng; Fangbin Song; Lei Li; Chao Xiao; Weiqiang Yang; Junming Xu
Journal:  Cell Death Dis       Date:  2020-06-12       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.